Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
MUC5B-promotervariant rs35705950 risicofactor voor RA-geassocieerde ILD
feb 2019 | ILD, Pneumonie, RA